Duopharma Biotech Berhad
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 7148.KL | BALPHARMA.NS | BDH.BO | AAREYDRUGS.NS | PHARMAID.BO | 1061.HK | |
|---|---|---|---|---|---|---|
| Market cap | 1.11B | 1.33B | 2.45B | 3.49B | 1.03B | 1.15B |
| P/E (TTM) | 10.5 | 18.4 | 21.0 | 74.4 | — | 4.4 |
| Forward P/E | 10.1 | — | 59.2 | — | — | 7.6 |
| Price/book | 1.4 | 1.6 | 3.2 | 2.1 | 2.2 | 0.5 |
| Dividend yield | 3.92% | 1.46% | 1.17% | — | — | 6.03% |
| 1-year change | −7.20% | +2.23% | −1.43% | +10.12% | −37.65% | −54.36% |
| Today | −0.86% | +1.72% | −0.20% | +0.08% | −0.82% | +2.76% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All 7148.KL news ›Duopharma Biotech Berhad Appoints Nik Fazila Binti Nik Mohamed Shihabuddin as Independent and Non-Executive Member of the Nomination and Remuneration Committee, Effective October 1, 2026
Duopharma Biotech Berhad announced the appointment of Puan Nik Fazila Binti Nik Mohamed Shihabuddin, age 59, as Independent and Non-Executive Member of the Nomination and Remuneration Committee,... Duopharma Biotech Berhad announced the…
Duopharma Biotech Berhad Announces the Resignation of Datin Paduka Kartini Binti Hj Abdul Manaf as Non Independent and Non Executive Chairman, Effective from August 31, 2026
DUOPHARMA BIOTECH BERHAD announced the resignation of Datin Paduka Kartini Binti Hj Abdul Manaf as Non Independent and Non Executive Chairman. Datin Paduka Kartini Binti Hj Abdul Manaf, aged 64, is... DUOPHARMA BIOTECH BERHAD announced the…
Duopharma Biotech Berhad Announces Resignation of Dr Hasnita Binti Hashim as Independent and Non-Executive Director, Effective September 30, 2026
Duopharma Biotech Berhad announced the resignation of Dr Hasnita Binti Hashim, age 65, as Independent and Non-Executive Director, effective September 30, 2026, to focus on other professional... Duopharma Biotech Berhad announced the…
Duopharma Biotech Berhad Announces the Appointment of Encik Shahin Farouque Bin Jammal Ahmad as Non Independent and Non Executive Chairman, Effective from September 1, 2026
DUOPHARMA BIOTECH BERHAD announced the appointment of Encik Shahin Farouque Bin Jammal Ahmad as Non Independent and Non Executive Chairman. Encik Shahin Farouque Bin Jammal Ahmad, aged 52, is... DUOPHARMA BIOTECH BERHAD announced the…
Duopharma Biotech Berhad Announces First Interim Dividend for the Financial Year Ending 31 December 2026, Payable on 21 September 2026
The Board of Directors of Duopharma Biotech Berhad announced first interim dividend of 1.5 sen per ordinary share for the financial year ending 31 December 2026, amounting to approximately MYR 14.43... Duopharma Biotech Berhad Announces…
Duopharma Biotech Berhad Redesignates Datuk Wira Arham Bin Abdul Rahman as Independent and Non Executive Chairman of the Nomination and Remuneration Committee from Independent and Non Executive Member of the Nomination and Remuneration Committee, Effective October 1, 2026
Duopharma Biotech Berhad announced the redesignation of Datuk Wira Arham Bin Abdul Rahman, age 63, as Chairman of the Nomination and Remuneration Committee from Member of the Nomination and... Duopharma Biotech Berhad announced the…
Duopharma Biotech Berhad Accepts Letter of Award for Supply of Recombinant Human Insulin 100 Iu/Ml Penfill/Refill and Reusable Insulin Pen to Ministry of Health's Facilities for Three Years
Duopharma Biotech Berhad announce that the Government has accepted the tender offer from Duopharma Sendirian Berhad, a wholly-owned subsidiary of Duopharma Biotech Berhad, to supply recombinant human...
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com8
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.